本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2023/7/211 分钟阅读
Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of a new drug application (NDA) for BUFFERIN (aspirin) tablets. The basis for the withdrawal is that the holder of the NDA has repeatedly failed to file required annual reports for this NDA.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →